ArticleBritish journal of cancer2012
Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model.
Article in British journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 32 citations in OpenAlex.
- Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy.Clinical pharmacokinetics · 2016Trial
- A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy.Japanese journal of clinical oncology · 2014Trial
- Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2014Trial
- From Fitting the Average to Fitting the Individual: A Cautionary Tale for Mathematical Modelers.Frontiers in oncology · 2022Article
- Optimum multi-drug regime for compartment model of tumour: cell-cycle-specific dynamics in the presence of resistance.Journal of pharmacokinetics and pharmacodynamics · 2021Article
- Mathematical models for cytarabine-derived myelosuppression in acute myeloid leukaemia.PloS one · 2019Article
- Evaluating optimal therapy robustness by virtual expansion of a sample population, with a case study in cancer immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Towards Quantitative Systems Pharmacology Models of Chemotherapy-Induced Neutropenia.CPT: pharmacometrics & systems pharmacology · 2017Review
- Computational oncology--mathematical modelling of drug regimens for precision medicine.Nature reviews. Clinical oncology · 2016Review
- Model-based approach to early predict prolonged high grade neutropenia in carboplatin-treated patients and guide G-CSF prophylactic treatment.Pharmaceutical research · 2015Article
- Complex pattern of interleukin-11-induced inflammation revealed by mathematically modeling the dynamics of C-reactive protein.Journal of pharmacokinetics and pharmacodynamics · 2014Article
- A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis.CPT: pharmacometrics & systems pharmacology · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundThis study was aimed to develop a new method for personalising chemotherapeutic and granulocyte colony-stimulating factor (G-CSF) combined schedules, and use it for suggesting efficacious chemotherapy with reduced neutropenia.
methodsClinical data from 38 docetaxel (Doc)-treated metastatic breast cancer patients were employed for validating a new pharmacokinetic/pharmacodynamics model for Doc, combined with a mathematical model for granulopoiesis. An optimisation procedure was constructed and used for selecting improved treatment schedules.
resultsThe combined model accurately predicted observed nadir timing (r=0.99), grade 3 or 4 neutropenia (86% success) and neutrophil counts over time in individual patients (r=0.63), and showed robustness to CYP3A-induced variability in Doc clearance. For average patients, the predicted optimal support for the standard chemotherapy regimen, Doc 100 μg m(-2) tri-weekly, is G-CSF, 300 μg, Q1D × 3, starting day 7 post-Doc. This regimen largely moderates chemotherapy-induced neutrophil nadir and neutropenia duration. The more intensive Doc dose, 150 mg m(-2), is optimally supported by the slightly less cost-effective G-CSF 300 μg, Q1D × 4, 5 days post-Doc. The latter regimen is optimal for borderline patients (2000 neutrophils per μl) under Doc, 100-150 mg m(-2) tri-weekly.
conclusionsThe new computational method can serve for tailoring efficacious cytotoxic and supportive treatments, minimising side effects to individual patients. Prospective clinical validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.